Sienna Biopharmaceuticals Company Description
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas.
It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin.
The company’s lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair.
The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016.
Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.
On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7.
It had filed for Chapter 11 bankruptcy on September 16, 2019.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Frederick C. Beddingfield |
Contact Details
Address: 30699 Russell Ranch Road Westlake Village, Delaware 91362 United States | |
| Phone | 818-629-2256 |
| Website | siennabio.com |
Stock Details
| Ticker Symbol | SNNAQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US82622H1086 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David E. I. Pyott M.A., M.B.A., M.D. | Strategic Advisor to the Board and Chief Executive Officer |
| Dr. Frederick C. Beddingfield III, M.D., Ph.D. | Chief Executive Officer, President and Director |
| Timothy K. Andrews Esq. | General Counsel and Corporate Secretary |
| Dr. Silvio Traversa BSc Ph.D. | Chief Scientific Officer |
| Sean Andrews | Vice President of Investor Relations |
| Theodore Schwartz | Head of Global Strategic Marketing |
| Michael Attar | Vice President and Head of Corporate Development |